$PSTI News

Last published 2y ago

2y agoAMT ECLP IRT NNN+5Independence Realty Trust Appoints Craig Macnab to its Board of DirectorsBusiness WireWaives Option to Classify Board Under Maryland Law Independence Realty Trust, Inc. (NYSE:IRT) ("IRT" or the "Company") today announced the appointment of Craig Macnab to its Board of Directors (the "Board"), effective
4y agoPSTI PLURPluri CEO Issues Shareholder UpdateGlobeNewswireHAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company") (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chi
4y agoPSTI PLURPluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesGlobeNewswireAs of July 26, 2022, Pluri's stock will trade under the symbol PLUR The new name reflects the Company's strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various life challeng
4y agoPSTIPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture SurgeryGlobeNewswireThe Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdi
4y agoPSTIPluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New PartnershipGlobeNewswireClosing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at: https://livestream.com/accounts/27896496/events/10
4y agoPSTIPluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood TransfusionsGlobeNewswireResults show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients. PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a fa
4y agoPSTIPluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint VentureGlobeNewswireHAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company ("Pluristem"), and Tnuva Group ("Tnuva Group" or "Tnuva"), Israel's largest food producer, today jointly announce
4y agoPSTIPluristem CEO Issues Shareholder UpdateGlobeNewswireHAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay. D
4y agoPSTIPluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food PlatformGlobeNewswirePluristem officially closed a deal with Israel's largest food brand Tnuva on February 24 2022, cementing an innovative partnership in the fast-growing industry of food tech Pluristem and Tnuva are proven pioneers in cell culture technology and consumer
4y agoBBIG HMHC IDRA PSTI+1Thinking about buying stock in Surgalign, Pluristem Therapeutics, Houghton Mifflin Harcourt, Idera Pharmaceuticals, or Vinco Ventures?PR NewswireNEW YORK, Jan. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRGA, PSTI, HMHC, IDRA, and BBIG.
4y agoADMP BITF DIDI HOOD+1Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?PR NewswireNEW YORK, Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP.
4y agoPSTIPluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19GlobeNewswireHAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) (the "Company"), a leading biotechnology company, today announced topline results from its Phase II dose escalation studies evaluating the safety and
4y agoPSTIPluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture SurgeryGlobeNewswireHaving recruited patients in the U.S., Europe and Israel, the Company anticipates topline results in the third calendar quarter of 2022 The Company will host a Key Opinion Leader online event on muscle regeneration following hip fracture surger
5y agoPSTIPluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX PlatformGlobeNewswireHAIFA, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading biotechnology company, today announced that it has received approval for an additional grant from the Israel Innovation Authority (IIA) to
5y agoAAZZF ABIO ACOGF ACST+81Investor Summit Group Provides Update on Upcoming Q4 Virtual SummitGlobeNewswireNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The Investor Summit Group, widely recognized for its reputation as the host of North America's largest independent investor conferences, will be hosting the upcoming Q4 Virtual Summit on November 16-17. The e
5y agoPSTIPluristem CEO Issues Shareholder UpdateGlobeNewswireHAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Dear Sha
5y agoCTGL PSTIPluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of DirectorsGlobeNewswireHAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Pro
5y agoPSTIPluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical ReadoutGlobeNewswireThe company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and Israel Topline results are expected during the fourth quarter of 2021 HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem The
5y agoPSTIPluristem to Receive €20M Non-Dilutive Funding from the European Investment BankGlobeNewswireHAIFA, Israel, May 25, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) (the "Company"), a leading biotechnology company, today announced the receipt of a "Disbursement Offer" in the amount of €20 million (approximately
5y agoPSTIPluristem Therapeutics Inc. Announces $30 Million Registered Direct OfferingGlobeNewswireHAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
5y agoPSTIPluristem Announces Uplisting to the Nasdaq Global Market®GlobeNewswireHAIFA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
5y agoPSTIPluristem Announces Appointments of Two Directors to BoardGlobeNewswireHAIFA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
5y agoPSTIPluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem’s ARDS Associated With COVID-19 Program to MexicoGlobeNewswireHAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
5y agoALSK MFLX ACW RCNI+30Elliott Management Nominates Independent, Highly Qualified Trustee Candidates to the Board of Public StoragePR NewswireElliott Associates, L.P. and Elliott International, L.P. (together, "Elliott"), which together have made a substantial investment in the common stock ...
5y agoPSTIPluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI StudyGlobeNewswireThe CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the...
5y agoPSTIPluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual MeetingGlobeNewswirePLX-R18 demonstrated significant clinical improvements in Hb, ANC, and PLT among the high-dose cohortPLX-R18 was found to be safe and well-toleratedTopline results from the full Phase I clinical trial...
6y agoPSTIWorld Experts in Infectious Diseases & Critical Care Form Pluristem’s COVID-19 Steering CommitteeGlobeNewswireHAIFA, Israel, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
6y agoPSTIPluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease StudyGlobeNewswireHAIFA, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
6y agoPSTIPluristem Expands its Phase II COVID-19 European Clinical Trial to IsraelGlobeNewswireHAIFA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
6y agoPSTIAbu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online EventBusiness WireBERLIN--(BUSINESS WIRE)--On Wednesday, September 30, 2020, Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading Israeli regenerative medicine company developing a platform of novel biological products, and the Abu Dhabi Stem Cells Center (ADSCC) unveiled their first joint projects in a presentation at the Malta Conferences Foundation (MCF), a global conference supported by kENUP Founda ...
6y agoPSTIAbu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online EventGlobeNewswireThe Malta Conferences address the shared desire to improve quality of life and political stability in the Middle East through scientific collaboration HAIFA, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE)...
6y agoPSTIPluristem CEO Issues Shareholder UpdateGlobeNewswireHAIFA, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
6y agoPSTIPluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical TrialGlobeNewswireHAIFA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
6y agoPSTIPluristem Announces End of Patient Enrollment in its Phase I Hematology StudyGlobeNewswireHAIFA, Israel, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
6y agoPSTIPluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of Severe Diseases Including COVID-19GlobeNewswireHAIFA, Israel, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
6y agoPSTIPluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in GermanyGlobeNewswireHAIFA, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
6y agoPSTIPluristem CEO Issues Shareholder Update on Clinical ProgramsGlobeNewswireHAIFA, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
6y agoPSTIPluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS TrialGlobeNewswireHAIFA, Israel, June 11, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
6y agoPSTIPluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.GlobeNewswire87.5% survival rate of patients on invasive mechanical ventilation injected with PLX cells75% of patients no longer in need of any mechanical ventilation 62.5% of the patients discharged alive from...
6y agoPSTIU.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 StudyGlobeNewswire140 patients with severe COVID-19 and ARDS to be treatedPrimary endpoint: ventilator free days during the main 28-day study period, secondary endpoint includes survival rate and ICU free days HAIFA,...
6y agoPSTIPluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 MillionGlobeNewswireHAIFA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
6y agoPSTIPluristem Recaps Investor & Analyst Call Reviewing European Investment Bank’s €50 Million FinancingGlobeNewswire• Elaborating on agreement terms and tranches schedule• Provides update on cash position and clinical program HAIFA, Israel, April 30, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc....
6y agoPSTIThe European Investment Bank (EIB), EU Delegation to Israel, the Israel Innovation Authority, and Pluristem Cordially Invite the Public to an Online Signing Ceremony on April 30, 2020GlobeNewswireHAIFA, Israel, April 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
6y agoPSTIPluristem Secures €50 Million Non-Dilutive Financing from the European Investment Bank to Support its COVID-19 Project and Phase III StudiesGlobeNewswireHAIFA, Israel, April 24, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
6y agoCNSP PSTI MNOV NVAX+1Several Potential Coronavirus Vaccines and Treatments Progressing Towards Human TrialsPR NewswireThe search for a vaccine for the global health crisis is being conducted by companies and countries around the world. Some are taking a cue from...
6y agoPSTIPluristem Expands its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access ProgramGlobeNewswireCleared by FDA to proceed with the treatment in U.S. under Coronavirus Treatment Acceleration Program (CTAP)Pluristem’s main focus: multinational clinical trial of PLX cells for treatment of...
6y agoMBRX AKER ABT PSTI+1Biotechs Fast Track Repurposing Existing Drugs for COVID-19 TreatmentsPR NewswireThe search for vaccines and treatments for the global health crises is now focusing on medicines that are presently approved for other ailments. A...
6y agoPSTIPluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory FailureGlobeNewswireAll treated patients were in Intensive Care Units (ICU) on ventilators and suffered from Acute Respiratory Distress Syndrome (ARDS)100% survival rate for all seven patients6 patients completed 1 week...
6y agoPSTIPluristem Treated First Three COVID-19 Patients in Israel under Compassionate UseGlobeNewswireExpects to treat more patients in Israel in the coming daysCompany is in discussions with regulators in the U.S. and Europe to define its clinical strategy for COVID-19 HAIFA, Israel, March 30, 2020...
6y agoPSTIPluristem Provides Update on COVID-19: Preparedness, Current Phase III Clinical Trials Status and Treatment Development ActivityGlobeNewswireHAIFA, Israel, March 26, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...